Mon, Mar 2, 2015, 3:34 AM EST - U.S. Markets open in 5 hrs 56 mins


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • ametrosixual ametrosixual Jul 1, 2013 2:53 PM Flag

    ``Nevermind Arikase Superiority SORRY MY BAD``- CEO


    Insmed’s Arikace met the primary endpoint of non-inferiority to Novartis AG (NOVN)’s Tobi in a late-stage study of cystic fibrosis patients with the bacterial infection Pseudomonas aeruginosa, the Monmouth Junction, New Jersey-based company said today in a statement. Earlier study results suggested the drug might establish superiority as a treatment compared with Novartis’s therapy, said Gregory R. Wade, an analyst at Wedbush Securities Inc.

    “That would have done two things: it would have improved its competitiveness in the marketplace, and it would have sped the rate at which it can make a registration filing in the United States,” Wade said.

    This topic is deleted.
18.54+0.38(+2.09%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.